Artiva Biotherapeutics, Inc.
ARTV · Biological Products, (No Diagnostic Substances) · 24.7M shares · +1303%/yr ↑ dilution · EDGAR filings ↗
Reference price $8.89 · est. market cap ~$220M — last insider purchase, 2026-06-16 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — NK-cell-therapy clinical, well-funded.
Strengths
- Liquidity — current ratio 8.6 (77th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Chronic dilutionShare count +1303%/yr over 1y (dilution, book value/share -96%)
- Cash burnNegative free cash flow (-79.3M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Exec changeRecent 8-K item 5.02 8-K ↗
- Insider buyingInsider buying — 9 open-market buy(s) by 2 insider(s) (cluster of 2 insiders, ~$104M, last 6mo) Form 4 ↗
- New fund positionNotable fund(s) opened this quarter: CITADEL ADVISORS LLC
- Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗
- Insider sellingInsider selling — 5 open-market sale(s) by 5 insider(s) (cluster of 5 insiders, ~$477,770, last 6mo) Form 4 ↗
- Revenue declineRevenue -100.0% YoY
- Notable holderHeld by 5 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP, CITADEL ADVISORS LLC +2 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
-76.3%
Return on assets
-64.0%
Revenue growth (QoQ)
-100.0%
Current ratio
8.6×
Free cash flow
-$79M
EBITDA
-$87M
Tangible book value
$110M
Cash & investments
$108M
Cash runway
5q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-16 | RA CAPITAL MANAGEMENT, L.P. | Buy | 125K | $8.89 |
| 2026-06-15 | RA CAPITAL MANAGEMENT, L.P. | Buy | 15K | $8.99 |
| 2026-06-12 | RA CAPITAL MANAGEMENT, L.P. | Buy | 391K | $8.57 |
| 2026-06-11 | RA CAPITAL MANAGEMENT, L.P. | Buy | 549K | $7.91 |
| 2026-06-10 | RA CAPITAL MANAGEMENT, L.P. | Buy | 103 | $7.00 |
| 2026-06-09 | RA CAPITAL MANAGEMENT, L.P. | Buy | 479K | $6.91 |
| 2026-05-19 | Bush Jennifer | Sell | 8.8K | $9.01 |
| 2026-05-19 | Aslan Fred | Sell | 27K | $9.01 |
| 2026-05-19 | Raymon Heather | Sell | 3.1K | $9.01 |
| 2026-05-19 | Horan Christopher | Sell | 7.0K | $9.01 |
| 2026-05-19 | Banerjee Subhashis | Sell | 7.0K | $9.01 |
| 2026-05-18 | Miralles Gines Diego | Grant | 78K | — |
| 2026-05-11 | GC Corp. | Buy | 347K | $11.52 |
| 2026-05-11 | GC Corp. | Buy | 1.1M | $11.52 |
| 2026-05-11 | RA CAPITAL MANAGEMENT, L.P. | Buy | 6.5M | $11.52 |
| 2026-03-10 | Huston Thad Allen | Grant | 220K | — |
| 2026-02-15 | Raymon Heather | Grant | 46K | — |
| 2026-02-15 | Raymon Heather | Tax withheld | 1.5K | $4.00 |
| 2026-02-15 | Horan Christopher | Grant | 117K | — |
| 2026-02-15 | Horan Christopher | Tax withheld | 2.2K | $4.00 |
| 2026-02-15 | Bush Jennifer | Grant | 117K | — |
| 2026-02-15 | Bush Jennifer | Tax withheld | 3.5K | $4.00 |
| 2026-02-15 | Banerjee Subhashis | Grant | 102K | — |
| 2026-02-15 | Aslan Fred | Grant | 367K | — |
| 2026-02-15 | Aslan Fred | Tax withheld | 15K | $4.00 |
| 2025-12-15 | Aslan Fred | Sell | 3.2K | $6.00 |
| 2025-12-12 | Horan Christopher | Grant | 107K | — |
| 2025-12-12 | Raymon Heather | Grant | 67K | — |
| 2025-12-12 | Bush Jennifer | Grant | 85K | — |
| 2025-12-12 | Aslan Fred | Grant | 869K | — |
| 2025-11-17 | Aslan Fred | Sell | 6.4K | $3.38 |
| 2025-11-15 | Horan Christopher | Tax withheld | 1.9K | $3.25 |
| 2025-11-15 | Krishnamohan Neha | Tax withheld | 3.5K | $3.25 |
| 2025-11-15 | Raymon Heather | Tax withheld | 1.4K | $3.25 |
| 2025-11-15 | Aslan Fred | Tax withheld | 6.3K | $3.25 |
| 2025-11-15 | Bush Jennifer | Tax withheld | 3.1K | $3.25 |
| 2025-10-17 | Aslan Fred | Sell | 26K | $6.00 |
| 2025-08-15 | Krishnamohan Neha | Tax withheld | 5.8K | $2.75 |
| 2025-08-15 | Aslan Fred | Sell | 26K | $2.73 |
| 2025-08-15 | Aslan Fred | Tax withheld | 4.5K | $2.75 |
| 2025-08-15 | Horan Christopher | Tax withheld | 3.6K | $2.75 |
| 2025-08-15 | Raymon Heather | Tax withheld | 1.6K | $2.75 |
| 2025-08-15 | Bush Jennifer | Tax withheld | 6.4K | $2.75 |
| 2025-05-15 | Krishnamohan Neha | Tax withheld | 1.3K | $2.13 |
| 2025-05-15 | Aslan Fred | Tax withheld | 4.5K | $2.13 |
| 2025-05-15 | Raymon Heather | Tax withheld | 745 | $2.13 |
| 2025-05-15 | Bush Jennifer | Tax withheld | 1.9K | $2.13 |
| 2025-05-15 | Horan Christopher | Tax withheld | 1.3K | $2.13 |
| 2025-04-08 | Banerjee Subhashis | Grant | 50K | — |
| 2025-03-05 | Aslan Fred | Grant | 200K | — |
| 2025-02-26 | Raymon Heather | Grant | 33K | — |
| 2025-02-26 | Graef Thorsten | Grant | 60K | — |
| 2025-02-26 | Horan Christopher | Grant | 60K | — |
| 2025-02-26 | Krishnamohan Neha | Grant | 60K | — |
| 2025-02-26 | Bush Jennifer | Grant | 87K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06991114 ↗ | AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs) | PHASE2 | Recruiting | 2028-01-01 |
| NCT06265220 ↗ | AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV | PHASE1 | Active Not Recruiting | 2027-08-01 |
| NCT05678205 ↗ | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors Breast Cancer, Gastric Cancer | PHASE1/PHASE2 | Withdrawn | 2027-04-01 |
| NCT04673617 ↗ | AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Non Hodgkin Lymphoma | PHASE1/PHASE2 | Completed | 2025-10-06 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-05-19 | Exec/director change | filing ↗ |
| 2026-05-08 | ResultsReg FDOtherExhibits | filing ↗ |
| 2026-05-08 | OtherExhibits | filing ↗ |
| 2026-03-10 | ResultsExhibits | filing ↗ |
| 2026-02-24 | Exec/director change | filing ↗ |
| 2026-02-19 | Exec/director change | filing ↗ |
| 2025-12-12 | Exec/director change | filing ↗ |
| 2025-11-12 | Reg FDOtherExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-05-19 | 2026-05-18 | 0001193125-26-229714 ↗ |
| 10-Q | 2026-05-08 | 2026-03-31 | 0001193125-26-213242 ↗ |
| 8-K | 2026-05-08 | 2026-05-08 | 0001193125-26-214711 ↗ |
| 8-K | 2026-05-08 | 2026-05-08 | 0001193125-26-213239 ↗ |
| 10-K/A | 2026-04-30 | 2025-12-31 | 0001193125-26-197115 ↗ |
| 8-K | 2026-03-10 | 2026-03-10 | 0001193125-26-100131 ↗ |
| 10-K | 2026-03-10 | 2025-12-31 | 0001193125-26-100135 ↗ |
| 8-K | 2026-02-24 | 2026-02-18 | 0001193125-26-067509 ↗ |
| 8-K | 2026-02-19 | 2026-02-18 | 0001193125-26-059716 ↗ |
| 8-K | 2025-12-12 | 2025-12-10 | 0001193125-25-317784 ↗ |
| 10-Q | 2025-11-12 | 2025-09-30 | 0001193125-25-275872 ↗ |
| 8-K | 2025-11-12 | 2025-11-12 | 0001193125-25-275902 ↗ |